Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Metrics to compare | AKTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAKTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.9x | −3.1x | −0.6x | |
PEG Ratio | 0.11 | 0.06 | 0.00 | |
Price / Book | −10.5x | 2.4x | 2.6x | |
Price / LTM Sales | - | 35.4x | 3.1x | |
Upside (Analyst Target) | - | 247.9% | 55.7% | |
Fair Value Upside | Unlock | 7.1% | 6.8% | Unlock |